1 / 21

Gonorrhea

Sexually Transmitted Disease Surveillance 2009 Division of STD Prevention. Gonorrhea. Gonorrhea—Rates, United States, 1941–2009. Rate (per 100,000 population). 500. 400. 300. 200. 100. 0. 1941. 1946. 1951. 1956. 1961. 1966. 1971. 1976. 1981. 1986. 1991. 1996. 2001. 2006.

iden
Download Presentation

Gonorrhea

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sexually Transmitted Disease Surveillance 2009 Division of STD Prevention Gonorrhea

  2. Gonorrhea—Rates, United States, 1941–2009 Rate (per 100,000 population) 500 400 300 200 100 0 1941 1946 1951 1956 1961 1966 1971 1976 1981 1986 1991 1996 2001 2006 Year

  3. Gonorrhea—Rates by Sex, United States, 1990–2009 Rate (per 100,000 population) 400 Men Women Total 300 200 100 0 1992 1990 1994 1996 1998 2000 2002 2004 2006 2008 Year

  4. Gonorrhea—Rates by Region, United States, 2000–2009 Rate (per 100,000 population) 300 West Midwest 250 Northeast South 200 150 100 50 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Year

  5. Gonorrhea—Rates by State, United States and Outlying Areas, 2009 34.9 VT NH MA RI CT NJ DE MD DC 8.0 8.6 30.4 30.6 73.1 54.8 111.2 113.5 432.7 8.3 10.9 23.5 44.1 29.4 92.4 7.2 42.8 87.2 Guam 33.5 147.0 13.9 81.4 55.2 77.2 66.4 139.2 154.7 12.5 107.2 57.2 63.2 26.2 100.3 89.4 89.6 109.8 150.4 127.5 Rate per 100,000 population 128.3 50.0 156.2 185.7 54.5 246.4 141.3 160.8 <19.0 (n = 8) 120.4 19.1–100.0 (n = 24) 113.9 204.0 144.3 >100.0 (n = 22) Virgin Islands 104.7 Puerto Rico 5.8 49.0 NOTE: The total rate of gonorrhea for the United States and outlying areas (Guam, Puerto Rico, and Virgin Islands) was 97.8 per 100,000 population.

  6. Gonorrhea—Rates by County, United States, 2009 Rate per 100,000 population <19.0 (n = 1,405) 19.1–100.0 (n = 1,129) >100.0 (n = 607)

  7. Gonorrhea—Rates by Age and Sex, United States, 2009 Men Rate (per 100,000 population) Women 750 600 450 300 150 0 0 150 300 450 600 750 Age 10–14 5.0 25.3 15–19 250.0 568.8 20–24 407.5 555.3 25–29 238.9 229.4 30–34 145.0 106.2 35–39 85.6 47.6 60.8 22.9 40–44 45–54 33.6 8.7 2.1 11.4 55–64 65+ 2.7 0.5 Total 92.2 105.7

  8. Gonorrhea—Rates by Age Among Women Aged 15–44 Years, United States, 2000–2009 Rate (per 100,000 population) Age Group 1,000 30–34 15–19 35–39 20–24 40–44 800 25–29 600 400 200 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Year

  9. Gonorrhea—Rates by Age Among Men Aged 15–44 Years, United States, 2000–2009 Rate (per 100,000 population) Age Group 750 30–34 15–19 35–39 20–24 40–44 25–29 600 450 300 150 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Year

  10. Gonorrhea—Rates by Race/Ethnicity, United States, 2000–2009 Rate (per 100,000 population) 800 700 600 500 American Indians/Alaska Natives Asians/Pacific Islanders 400 Blacks 300 Hispanics Whites 200 100 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Year

  11. Gonorrhea—Cases by Reporting Source and Sex, United States, 2000–2009 Cases (in thousands) 200 Non-STD* Clinic, Men Non-STD Clinic, Women STD Clinic, Men 160 STD Clinic, Women 120 80 40 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Year * STD = sexually transmitted disease.

  12. Gonorrhea—Percentage of Reported Cases by Sex and Selected Reporting Sources, United States, 2009 Percentage Private Physician/HMO* 35 STD* Clinic 30 Other HD* Clinic Family Planning Clinic 25 Emergency Room 20 15 10 5 0 Men Women * HMO = health maintenance organization; STD = sexually transmitted disease; HD = health department. NOTE: These categories represent 71.9% of cases with known reporting source. Of all cases, 10.3% had a missing or unknown reporting source.

  13. Gonorrhea—Positivity Among Women Aged 15–24 Years Tested in Family Planning Clinics, by State, Infertility Prevention Project, United States and Outlying Areas, 2009 0.3 VT NH MA RI CT NJ DE MD DC 0.2 0.3 0.6 1.2 1.3 2.5 0.0 1.1 0.3 0.4 0.1 2.7 0.1 0.5 1.4 0.2 0.8 0.5 0.8 3.4 1.8 1.4 1.1 0.3 0.2 0.4 1.0 1.0 1.0 0.5 1.0 1.2 0.6 Positivity (%) 0.8 0.4 1.9 2.0 1.6 2.0 2.4 1.8 * (n = 4) 2.1 2.0 <1.0 (n = 24) 0.2 1.2 1.0–1.9 (n = 16) Virgin Islands 2.0 Puerto Rico 0.1 >2.0 (n = 9) 0.5 * States/areas not meeting minimum inclusion criteria. NOTE: Includes states and outlying areas that reported positivity data on at least 500 women aged 15–24 years who were screened during 2009.

  14. Gonococcal Isolate Surveillance Project (GISP)—Location of Participating Sentinel Sites and Regional Laboratories, United States, 2009 Seattle Minneapolis Portland Detroit New York City Philadelphia San Francisco Cleveland Chicago Baltimore Cincinnati Las Vegas Denver Kansas City Richmond Greensboro Los Angeles Oklahoma City Phoenix Orange Co. Albuquerque San Diego Atlanta Sentinel Sites Birmingham Dallas Sites and Regional Labs Tripler AMC New Orleans Honolulu Miami

  15. Gonococcal Isolate Surveillance Project (GISP)—Distribution of Minimum Inhibitory Concentrations (MICs) to Ceftriaxone Among GISP Isolates, 2005–2009 Percentage 100 2005 2006 2007 80 2008 2009 60 40 20 0 0.015 0.03 0.06 0.125 0.25 <0.008 MICs (µg/ml)

  16. Gonococcal Isolate Surveillance Project (GISP)—Distribution of Minimum Inhibitory Concentrations (MICs) to Cefixime Among GISP Isolates, 2005–2006 and 2009 Percentage 100 2005 2006 80 2009 60 40 20 0 <0.015 0.03 0.06 0.125 0.25 0.5 MICs (µg/ml) NOTE: Isolates were not tested for cefixime susceptibility in 2007 and 2008.

  17. Gonococcal Isolate Surveillance Project (GISP)—Distribution of Minimum Inhibitory Concentrations (MICs) to Azithromycin Among GISP Isolates, 2005–2009 Percentage 40 2005 2006 2007 30 2008 2009 20 10 0 0.06 0.125 0.25 0.5 1 2 4 8 16 <0.03 MICs (µg/ml)

  18. Gonococcal Isolate Surveillance Project (GISP)—Percentage of Neisseria gonorrhoeae Isolates with Resistance or Intermediate Resistance to Ciprofloxacin, 1990–2009 Percentage 20 Resistance Intermediate Resistance 15 10 5 0 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Year NOTE: Resistant isolates have ciprofloxacin minimum inhibitory concentrations (MICs) >1 µg/ml. Isolates with intermediate resistance have ciprofloxacin MICs of 0.125–0.5 µg/ml. Susceptibility to ciprofloxacin was first measured in GISP in 1990.

  19. Gonococcal Isolate Surveillance Project (GISP)—Penicillin, Tetracycline, and Ciprofloxacin Resistance Among GISP Isolates, 2009 1.1% 0.9% 2.2% 5.5% 2.1% Susceptible 7.9% PenR TetR 3.8% QRNG PenR/TetR PenR/QRNG 76.5% TetR/QRNG PenR/TetR/QRNG NOTE: PenR = penicillinase producing Neisseriagonorrhoeaeand chromosomally mediated penicillin-resistant N. gonorrhoeae; TetR = chromosomally and plasmid mediated tetracycline-resistant N. gonorrhoeae; and QRNG = quinolone-resistant N. gonorrhoeae.

  20. Gonococcal Isolate Surveillance Project (GISP)—Drugs Used to Treat Gonorrhea Among GISP Participants, 1988–2009 Percentage 100 Other Tetracyclines Penicillins Ofloxacin 80 Ciprofloxacin 60 Cefixime Ceftriaxone 250 mg 40 20 Spectinomycin Ceftriaxone 125 mg Other Cephalosporins 0 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 Year NOTE: For 2009, “Other” includes no therapy (1.5%), azithromycin 2 g (1.7%), and other less frequently used drugs.

  21. National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of STD Prevention

More Related